A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.

(2019) Anne Demols et al.   JOURNAL OF CLINICAL ONCOLOGY

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

(2019) Angela Lamarca et al.   JOURNAL OF CLINICAL ONCOLOGY

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

(2019) Tanios S Bekaii-Saab et al.   LANCET ONCOLOGY

The association between preoperative serum interleukin-6 levels and postoperative prognosis in patients with T2 gallbladder cancer

(2018) Jianfa Wang et al.   JOURNAL OF SURGICAL ONCOLOGY

Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody TRC105

(2018) Yingmiao Liu et al.   MOLECULAR CANCER THERAPEUTICS

A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma

(2018) Weijing Sun et al.   CANCER

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice

(2018) Sang Eun Yoon et al.   OncoTargets and Therapy

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

(2017) Valeria Simone et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.

(2017) A. J. Weickhardt et al.   JOURNAL OF CLINICAL ONCOLOGY

Biliary cancer: Utility of next-generation sequencing for clinical management

(2016) Milind Javle et al.   CANCER

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

(2015) Juan W Valle et al.   LANCET ONCOLOGY

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jin Li et al.   LANCET ONCOLOGY

Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

(2015) Y. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Signal Transduction in Cancer

(2015) R. Sever et al.   Cold Spring Harbor Perspectives in Medicine

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

(2014) Mitesh J. Borad et al.   PLoS Genetics

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

(2013) A. B. Nixon et al.   CLINICAL CANCER RESEARCH

Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma

(2013) Sumera Rizvi et al.   GASTROENTEROLOGY

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

(2013) Yasuhito Arai et al.   HEPATOLOGY

Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy

(2013) Supak Yothaisong et al.   TUMOR BIOLOGY

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

(2013) Yingmiao Liu et al.   Cancer Medicine

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas

(2009) James E. Everhart et al.   GASTROENTEROLOGY